Houben Philipp, Hohenberger Ralph, Yamanaka Kenya, Büchler Markus W, Schemmer Peter
Department of General, Visceral, and Transplant Surgery, University Hospital Heidelberg, Heidelberg, Germany.
Ann Transplant. 2018 Jul 13;23:475-480. doi: 10.12659/AOT.909165.
BACKGROUND Pre-transplant assessment of the graft for liver transplantation is crucial. Based on experimental data, this study was designed to assess both nuclear high mobility group box-1 (HMGB-1) protein and arginine-specific proteolytic activity (ASPA) in the graft effluent. MATERIAL AND METHODS In a non-interventional trial, both HMGB-1 and ASPA were measured in the effluent of 30 liver grafts after cold storage before transplantation. Values of HMGB-1 and ASPA levels were compared with established prognostic parameters such as the donor risk index, balance of risk score, and Donor-Model for End-Stage Liver Disease. RESULTS The early allograft dysfunction (EAD) was best predicted by recipient age (p=0.026) and HMGB-1 (p=0.031). HMGB -1 thresholds indicated the likelihood for initial non-function (1608 ng/ml, p=0.004) and EAD (580 ng/ml, p=0.017). The multivariate binary regression analysis showed a 21-fold higher (95% CI: 1.6-284.5, p=0.022) risk for EAD in cases with levels exceeding 580 ng/ml. The ASPA was lower in cases of initial non-function (p=0.028) but did not correlate with the rate of EAD (p=0.4). CONCLUSIONS This study demonstrates the feasibility of HMGB-1 detection in the graft effluent after cold storage. Along with conventional prognostic scores, it may be helpful to predict the early fate of a graft in human liver transplantation.
背景 肝移植移植物的移植前评估至关重要。基于实验数据,本研究旨在评估移植物流出液中的核高迁移率族蛋白B1(HMGB-1)和精氨酸特异性蛋白水解活性(ASPA)。材料与方法 在一项非干预性试验中,对30例肝移植物在移植前冷保存后的流出液进行HMGB-1和ASPA检测。将HMGB-1和ASPA水平值与既定的预后参数进行比较,如供体风险指数、风险平衡评分和终末期肝病供体模型。结果 受者年龄(p=0.026)和HMGB-1(p=0.031)对早期移植物功能障碍(EAD)的预测效果最佳。HMGB-1阈值表明初始无功能(1608 ng/ml,p=0.004)和EAD(580 ng/ml,p=0.017)的可能性。多因素二元回归分析显示,水平超过580 ng/ml的病例发生EAD的风险高21倍(95%CI:1.6-284.5,p=0.022)。初始无功能病例的ASPA较低(p=0.028),但与EAD发生率无关(p=0.4)。结论 本研究证明了冷保存后移植物流出液中检测HMGB-1的可行性。与传统预后评分一起,它可能有助于预测人类肝移植中移植物的早期转归。